Loading...
•
Mar 31
Eli Lilly Q1 2025 Earnings Report
Lilly reported strong Q1 2025 results with double-digit revenue and EPS growth driven by Mounjaro and Zepbound.
Key Takeaways
Eli Lilly delivered a robust performance in Q1 2025, with 45% revenue growth propelled by Mounjaro and Zepbound sales. Both GAAP and non-GAAP earnings rose over 20%, and the company reaffirmed its full-year guidance despite elevated R&D costs.
Revenue rose 45% YoY to $12.73 billion, driven by strong volume growth from Mounjaro and Zepbound.
GAAP EPS was $3.06, up 23%; non-GAAP EPS was $3.34, up 29%.
Net income reached $2.76 billion on a reported basis.
Positive Phase 3 results for oral GLP-1 orforglipron boosted pipeline momentum.
Eli Lilly
Eli Lilly
Eli Lilly Revenue by Segment
Eli Lilly Revenue by Geographic Location
Revenue by Segment
Mounjaro Revenue
CapyFin.comZepbound Revenue
CapyFin.comVerzenio Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comOutside U.S. Revenue
CapyFin.com Forward Guidance
Lilly reaffirmed 2025 revenue guidance between $58.0B and $61.0B but adjusted EPS guidance downward due to Q1 IPR&D charges.
Positive Outlook
- Revenue guidance maintained at $58.0B to $61.0B.
- Performance margin guidance unchanged.
- Strong momentum from Mounjaro and Zepbound expected to continue.
- Multiple pipeline advancements including orforglipron Phase 3 success.
- Manufacturing investments to support increased product demand.
Challenges Ahead
- EPS guidance lowered due to $1.57B in acquired IPR&D charges.
- Higher tax rate forecasted at 17%, up from 16%.
- Expense pressure from increased R&D and marketing investments.
- Net losses on equity investments affecting reported results.
- Unfavorable pricing trends continue to impact revenue.
Revenue & Expenses
Visualization of income flow from segment revenue to net income